What is the 13F Pro Quality Score for NAGE?

13F Pro ranks Niagen Bioscience, Inc. (NAGE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NAGE's current score at https://13fpro.ai/research/NAGE (free sign-up required for the full ranking).

Where does 13F Pro source NAGE data?

All Niagen Bioscience, Inc. fundamentals and ownership data come directly from SEC EDGAR. Niagen Bioscience, Inc. files with the SEC under CIK 1386570. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NAGE in?

Niagen Bioscience, Inc. (NAGE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives NAGE's revenue?

Per Niagen Bioscience, Inc.'s latest 10-Q filed with the SEC on 2026-05-06, the biggest revenue drivers are: Consumer Products ($22.4M, +4% YoY); Ingredients ($8.6M, +5% YoY); Analytical Reference Standards and Services ($0.4M, -48% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/NAGE.

What are NAGE's largest expenses?

Niagen Bioscience, Inc.'s latest 10-Q reports these as the largest expense items: General and Administrative ($7.2M, +40% YoY); Sales and Marketing ($9.7M, +19% YoY); Research and Development ($1.5M, +18% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is NAGE research updated on 13F Pro?

NAGE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Niagen Bioscience, Inc.(NAGE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1386570 NAGE stock profile & AI dashboard →

13F Pro Quality Score

67.0/100

Rank #485 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

82.7/100

Profitability

83.8/100

Balance Sheet

95.9/100

Earnings Quality

30.0/100

Free Cash Flow

61.6/100

Institutional Flow

85.0/100

Revenue Scale

19.9/100

Dilution Risk

26.9/100

NAGE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Niagen Bioscience, Inc. (NAGE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NAGE at 67.0/100 on a 32-signal composite quality model, placing it at rank #485 of 2,879 stocks — the top 25% of the AI-ranked universe. NAGE scores in the top quartile across balance sheet strength (95.9), institutional flow (85.0), profitability (83.8). Areas of concern include revenue scale (19.9) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Niagen Bioscience, Inc. reports quarterly revenue of $31.5M, net income of $6.3M, free cash flow of $-1.2M. Top institutional holders of NAGE by reported 13-F value include BlackRock,, SteelPeak Wealth,, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP, based on the most recent SEC filings. NAGE trades on the Nasdaq exchange and files with the SEC under CIK 1386570. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NAGE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Niagen Bioscience, Inc. directly from SEC EDGAR. Niagen Bioscience, Inc.'s 13F Pro composite quality score has ranged between 8 and 79 since 2024, currently 67.0 — an improving long-term trajectory across 43 quarterly and live scoring snapshots.

What's Driving NAGE's Business? Latest 10-Q Breakdown

AI-extracted from Niagen Bioscience, Inc.'s 10-Q filed 2026-05-06 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales grew 3% YoY to $31.5M as Consumer Products and Ingredients segments expanded, while a $4.8M gain on the February 2026 sale of the Analytical Reference Standards business lifted net income to $6.3M.

Biggest Revenue Drivers

Total revenue: $31.5M+3% YoY

Consumer Products$22.4M+4% YoY

Tru Niagen sales increased $0.9M driven by e-commerce channel growth of ~$2.4M, partially offset by lower A.S. Watson distributor sales of $2.4M.

Ingredients$8.6M+5% YoY

Growth driven by higher food-grade Niagen sales (~$0.3M) and other ingredients (~$0.2M), partly offset by lower pharmaceutical-grade Niagen sales.

Analytical Reference Standards and Services$0.4M-48% YoY

Segment sold on February 24, 2026; current quarter reflects partial-period activity only; divestiture completed in Q1.

Largest Expense Items

General and Administrative$7.2M+40% YoY

$1.4M increase in provisions for credit losses (prior year had $1.3M recovery) and $0.7M higher share-based compensation expense.

Sales and Marketing$9.7M+19% YoY

Increased investments in brand growth and planned commercial activities, primarily within Consumer Products; higher advertising and marketing expenditures plus personnel costs.

Research and Development$1.5M+18% YoY

Increase of $0.1M in Pharmaceuticals segment for NAD precursor development; $0.1M higher spending on Niagen Plus research and scientific engagement activities.

Watch Items from the Filing

Three customers represent 52.2% of trade receivables as of March 31, 2026; Customer A at 25.2%, Customer B at 15.1%, Customer C at 11.9%. A.S. Watson distributor sales declined $2.4M YoY.
Grace supply agreement requires minimum annual NRC purchases of ~$18.5M through March 2027; Grace holds exclusive patents for crystalline NRC, limiting alternative suppliers.
Patent litigation with Elysium: on October 28, 2024, court granted Elysium $9.2M in attorney fees and costs; Company filed appeal to Federal Circuit on November 25, 2024; reasonably possible contingent liability of ~$10.4M including post-judgment interest.
Divestiture of Analytical Reference Standards segment completed February 24, 2026 for $6.0M, generating $4.8M net gain. Transition services agreement to provide temporary support for up to six months; costs absorbed by remaining operations.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$31.5M

Net Income

Q1 2026

$6.3M

Free Cash Flow

Q1 2026

$-1.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+41.0% YoY

$83.6MFY 2023

FY18 $31.6MFY19 $46.3MFY20 $59.3MFY23 $83.6M

Net Income

+75.2% YoY

$-4.9MFY 2023

FY18 $-33.3MFY19 $-32.1MFY20 $-19.9MFY23 $-4.9M

Operating Income

+71.8% YoY

$-5.6MFY 2023

FY18 $-33.2MFY19 $-31.3MFY20 $-19.9MFY23 $-5.6M

EPS (Diluted)

+78.8% YoY

$-0.07FY 2023

FY18 —FY19 —FY20 $-0.33FY23 $-0.07

Total Assets

+43.3% YoY

$55.0MFY 2023

FY18 $42.2MFY19 $40.2MFY20 $38.4MFY23 $55.0M

Total Debt

—FY 2023

FY18 $137.0KFY19 —FY20 —FY23 —

Op. Cash Flow

+167.1% YoY

$7.1MFY 2023

FY18 $-20.9MFY19 $-20.4MFY20 $-10.6MFY23 $7.1M

Metric	FY 2023	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Revenue	$83.6M +41.0%	$59.3M +28.0%	$46.3M +46.7%	$31.6M +48.8%	$21.2M -2.1%	$21.7M
Net Income	$-4.9M +75.2%	$-19.9M +38.0%	$-32.1M +3.5%	$-33.3M -192.8%	$-11.4M -288.6%	$-2.9M
Operating Income	$-5.6M +71.8%	$-19.9M +36.6%	$-31.3M +5.6%	$-33.2M -102.6%	$-16.4M -463.7%	$-2.9M
EPS (Diluted)	$-0.07 +78.8%	$-0.33	—	—	—	—
Total Assets	$55.0M +43.3%	$38.4M -4.7%	$40.2M -4.7%	$42.2M -32.7%	$62.7M +217.6%	$19.8M
Total Debt	—	—	—	$137.0K -55.8%	$310.0K -9.9%	$344.0K
Operating Cash Flow	$7.1M +167.1%	$-10.6M +48.1%	$-20.4M +2.2%	$-20.9M -113.3%	$-9.8M -233.9%	$-2.9M

AI Insight: NAGE Financial Trends

Revenue growth stalled at $34M in Q4 2025 and declined to $31M in Q1 2026, while operating cash flow turned negative.

• Revenue grew from $23M in Q2 2024 to $34M in Q3 2025, then declined to $31M in Q1 2026.

• Operating cash flow turned negative at $-1M in Q1 2026 after peaking at $9M in Q4 2024.

• Equity steadily increased from $31M in Q2 2024 to $82M in Q1 2026.

⚠ Revenue momentum has stalled with sequential declines in the latest quarter after strong growth through Q3 2025.

⚠ Operating cash flow volatility with negative $1M in Q1 2026 following $1M in Q4 2025.

AI Insight: NAGE Ratio Trends

Niagen's profitability peaked in Q4 2024 with 24.4% operating margin and 61.7% ROIC, but has since declined sharply with ROIC falling to 7.7% in Q1 2026.

• Operating margin collapsed from Q4 2024's peak of 24.4% to just 5.0% in Q1 2026.

• ROIC plummeted from 61.7% in Q4 2024 to 7.7% in Q1 2026, indicating significant capital efficiency deterioration.

• Company turned profitable after Q2 2024 losses, with net margin reaching 20.1% in Q1 2026.

⚠ Sharp disconnect between net margin (20.1%) and operating margin (5.0%) in Q1 2026 suggests non-operating income dependency.

⚠ Quarterly volatility in all profitability metrics indicates unstable operating performance and potential seasonality issues.

Get alerted when NAGE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Niagen Bioscience, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NAGE

BlackRock, Inc.
$17.1M3,871,619 sh
SteelPeak Wealth, LLC
$14.9M3,373,000 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$10.5M2,378,437 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.5M2,149,277 sh
Qube Research & Technologies Ltd
$7.6M1,714,639 sh
UBS Group AG
$6.2M1,405,531 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.9M1,344,921 sh
RENAISSANCE TECHNOLOGIES LLC
$5.9M1,328,843 sh
GOLDMAN SACHS GROUP INC
$5.5M1,251,959 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$5.4M1,221,494 sh

Fund	Value	Shares
BlackRock, Inc.	$17.1M	3,871,619
SteelPeak Wealth, LLC	$14.9M	3,373,000
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$10.5M	2,378,437
VANGUARD CAPITAL MANAGEMENT LLC	$9.5M	2,149,277
Qube Research & Technologies Ltd	$7.6M	1,714,639
UBS Group AG	$6.2M	1,405,531
GEODE CAPITAL MANAGEMENT, LLC	$5.9M	1,344,921
RENAISSANCE TECHNOLOGIES LLC	$5.9M	1,328,843
GOLDMAN SACHS GROUP INC	$5.5M	1,251,959
VANGUARD PORTFOLIO MANAGEMENT LLC	$5.4M	1,221,494

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NAGE on your watchlist

Track score changes the day Niagen Bioscience, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NAGE a good stock to buy?

13F Pro's AI-powered analysis of Niagen Bioscience, Inc. (NAGE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NAGE are available on the NAGE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NAGE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NAGE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Niagen Bioscience, Inc.'s investment landscape.